Plasma Metabolites Associated with Coffee Consumption: A Metabolomic Approach within the PREDIMED Study.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
08 May 2019
Historique:
received: 05 04 2019
revised: 02 05 2019
accepted: 03 05 2019
entrez: 11 5 2019
pubmed: 11 5 2019
medline: 7 1 2020
Statut: epublish

Résumé

Few studies have examined the association of a wide range of metabolites with total and subtypes of coffee consumption. The aim of this study was to investigate associations of plasma metabolites with total, caffeinated, and decaffeinated coffee consumption. We also assessed the ability of metabolites to discriminate between coffee consumption categories. This is a cross-sectional analysis of 1664 participants from the PREDIMED study. Metabolites were semiquantitatively profiled using a multiplatform approach. Consumption of total coffee, caffeinated coffee and decaffeinated coffee was assessed by using a validated food frequency questionnaire. We assessed associations between 387 metabolite levels with total, caffeinated, or decaffeinated coffee consumption (≥50 mL coffee/day) using elastic net regression analysis. Ten-fold cross-validation analyses were used to estimate the discriminative accuracy of metabolites for total and subtypes of coffee. We identified different sets of metabolites associated with total coffee, caffeinated and decaffeinated coffee consumption. These metabolites consisted of lipid species (e.g., sphingomyelin, phosphatidylethanolamine, and phosphatidylcholine) or were derived from glycolysis (alpha-glycerophosphate) and polyphenol metabolism (hippurate). Other metabolites included caffeine, 5-acetylamino-6-amino-3-methyluracil, cotinine, kynurenic acid, glycocholate, lactate, and allantoin. The area under the curve (AUC) was 0.60 (95% CI 0.56-0.64), 0.78 (95% CI 0.75-0.81) and 0.52 (95% CI 0.49-0.55), in the multimetabolite model, for total, caffeinated, and decaffeinated coffee consumption, respectively. Our comprehensive metabolic analysis did not result in a new, reliable potential set of metabolites for coffee consumption.

Identifiants

pubmed: 31072000
pii: nu11051032
doi: 10.3390/nu11051032
pmc: PMC6566346
pii:
doi:

Substances chimiques

Coffee 0
Caffeine 3G6A5W338E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK102896
Pays : United States
Organisme : NIH HHS
ID : R01DK102896
Pays : United States

Références

Br J Nutr. 2010 Jun;103(12):1808-16
pubmed: 20102675
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Int J Epidemiol. 2017 Dec 1;46(6):1958-1967
pubmed: 29025033
Front Pharmacol. 2012 Oct 10;3:173
pubmed: 23087643
Am J Clin Nutr. 2014 Jul;100(1):208-17
pubmed: 24740205
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1052-60
pubmed: 25999212
Adv Nutr. 2015 Jan 15;6(1):5-18
pubmed: 25593140
Am J Epidemiol. 2001 Feb 15;153(4):353-62
pubmed: 11207153
Am J Physiol. 1995 Jun;268(6 Pt 1):E1192-8
pubmed: 7611396
Eur J Gastroenterol Hepatol. 2000 May;12(5):529-33
pubmed: 10833096
Eur J Clin Nutr. 2012 Aug;66(8):872-7
pubmed: 22713771
Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4472-E4481
pubmed: 28507131
J Intern Med. 2018 Jun;283(6):544-557
pubmed: 29381822
Compr Rev Food Sci Food Saf. 2017 Jan;16(1):124-140
pubmed: 33371546
Diabetes Care. 2009 Nov;32 Suppl 2:S237-45
pubmed: 19875558
Am J Clin Nutr. 2014 Sep;100(3):891-900
pubmed: 25057154
PLoS One. 2014 Apr 08;9(4):e93474
pubmed: 24713823
J Am Coll Nutr. 2015;34(3):212-23
pubmed: 25738401
Br J Nutr. 1999 Aug;82(2):125-30
pubmed: 10743484
Sci Rep. 2017 Oct 20;7(1):13670
pubmed: 29057986
J Chromatogr A. 2011 Jul 22;1218(29):4678-88
pubmed: 21676405
Cancer Sci. 2009 Apr;100(4):715-21
pubmed: 19469016
Circulation. 2017 May 23;135(21):2028-2040
pubmed: 28280233
Am J Clin Nutr. 2018 Jun 1;107(6):941-947
pubmed: 29771289
Int J Epidemiol. 2012 Apr;41(2):377-85
pubmed: 21172932
J Clin Invest. 2017 Dec 1;127(12):4394-4402
pubmed: 29083323
Nat Med. 2015 Jun;21(6):638-46
pubmed: 26005855
Diabetes Care. 2012 Jan;35(1):173-4
pubmed: 22100959
Gastroenterology. 2004 Mar;126(3):724-31
pubmed: 14988826
J Mass Spectrom. 2005 Mar;40(3):307-16
pubmed: 15685651
J Chromatogr A. 2011 Jan 21;1218(3):491-7
pubmed: 21167490
BMJ. 2017 Nov 22;359:j5024
pubmed: 29167102
N Engl J Med. 2018 Jun 21;378(25):e34
pubmed: 29897866
Anal Chim Acta. 2011 Jan 31;685(2):204-11
pubmed: 21168570
Int J Sport Nutr. 1992 Dec;2(4):386-96
pubmed: 1299508
Psychosom Med. 2004 May-Jun;66(3):411-21
pubmed: 15184705
Mol Nutr Food Res. 2009 Nov;53(11):1357-65
pubmed: 19810022
Am J Clin Nutr. 2018 Jul 1;108(1):163-173
pubmed: 29982310
Diabetes. 2005 Mar;54(3):629-37
pubmed: 15734837
Nutr Metab (Lond). 2016 Nov 17;13:81
pubmed: 27891166
Nutrients. 2018 Dec 01;10(12):
pubmed: 30513727
J Agric Food Chem. 2017 Mar 1;65(8):1613-1619
pubmed: 28158941
Diabetes Care. 2014 Feb;37(2):569-86
pubmed: 24459154
Drug Metab Dispos. 2009 Aug;37(8):1749-58
pubmed: 19460943
J Hum Nutr Diet. 2003 Dec;16(6):411-20
pubmed: 19774754

Auteurs

Christopher Papandreou (C)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain. papchris10@gmail.com.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. papchris10@gmail.com.

Pablo Hernández-Alonso (P)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain. pablo1280@gmail.com.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. pablo1280@gmail.com.

Mònica Bulló (M)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain. monica.bullo@urv.cat.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. monica.bullo@urv.cat.

Miguel Ruiz-Canela (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. mcanela@unav.es.
University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, 31009 Pamplona, Spain. mcanela@unav.es.

Edward Yu (E)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. edy356@mail.harvard.edu.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. edy356@mail.harvard.edu.

Marta Guasch-Ferré (M)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain. mguasch@hsph.harvard.edu.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. mguasch@hsph.harvard.edu.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. mguasch@hsph.harvard.edu.

Estefanía Toledo (E)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. etoledo@unav.es.
University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, 31009 Pamplona, Spain. etoledo@unav.es.

Courtney Dennis (C)

Broad Institute of MIT and Harvard University, Cambridge, MA 02142, USA. cdennis@broadinstitute.org.

Amy Deik (A)

Broad Institute of MIT and Harvard University, Cambridge, MA 02142, USA. adeik@broadinstitute.org.

Clary Clish (C)

Broad Institute of MIT and Harvard University, Cambridge, MA 02142, USA. clary@broadinstitute.org.

Cristina Razquin (C)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. crazquin@unav.es.
University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, 31009 Pamplona, Spain. crazquin@unav.es.

Dolores Corella (D)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. dolores.corella@uv.es.
Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain. dolores.corella@uv.es.

Ramon Estruch (R)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. RESTRUCH@clinic.ub.es.
Department of Internal Medicine, Department of Endocrinology and Nutrition Institut d' Investigacions Biomediques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08007 Barcelona, Spain. RESTRUCH@clinic.ub.es.

Emilio Ros (E)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. eros@clinic.ub.es.
Lipid Clinic, Department of Endocrinology and Nutrition Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08007 Barcelona, Spain. eros@clinic.ub.es.

Montserrat Fitó (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. MFito@imim.es.
Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Research Institute (IMIM), 08003 Barcelona, Spain. MFito@imim.es.

Fernando Arós (F)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. lfaborau@gmail.com.
Department of Cardiology, University Hospital of Álava, 01009 Vitoria, Spain. lfaborau@gmail.com.

Miquel Fiol (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. miquelfiol@yahoo.es.
Illes Balears Health Research Institute (IdISBa), Hospital Son Espases, 07120 Palma de Mallorca, Spain. miquelfiol@yahoo.es.

José Lapetra (J)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. jlapetra@ono.com.
Department of Family, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41013 Sevilla, Spain. jlapetra@ono.com.

Cristina Ruano (C)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. cristina.ruano@ulpgc.es.
Department of Clinical Sciences, University of Las Palmas de Gran Canaria, 35001 Las Palmas, Spain. cristina.ruano@ulpgc.es.

Liming Liang (L)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. lliang@hsph.harvard.edu.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. lliang@hsph.harvard.edu.

Miguel A Martínez-González (MA)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. mamartinez@unav.es.
University of Navarra, Department of Preventive Medicine and Public Health, IdiSNA, 31009 Pamplona, Spain. mamartinez@unav.es.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. mamartinez@unav.es.

Frank B Hu (FB)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. nhbfh@channing.harvard.edu.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. nhbfh@channing.harvard.edu.
Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, MA 02115, USA. nhbfh@channing.harvard.edu.

Jordi Salas-Salvadó (J)

Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain. jordi.salas@urv.cat.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. jordi.salas@urv.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH